Century Therapeutics (IPSC) Long-Term Investments (2020 - 2026)

Century Therapeutics (IPSC) has reported Long-Term Investments for 7 consecutive years, with $82.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 296.7% year-over-year to $82.2 million; the TTM figure through Mar 2026 stood at $82.2 million (up 296.7% YoY), while the FY2024 annual figure was $30.8 million, down 65.41% from the prior year.
• Long-Term Investments improved to $82.2 million in Q1 2026 per IPSC's latest filing, from $2.7 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $144.6 million in Q2 2023 and bottomed at $2.7 million in Q2 2025.
• Historically, Long-Term Investments has averaged $66.2 million across 5 years, with a median of $57.9 million in 2024.
• Annual changes were most pronounced in 2025 — Long-Term Investments sank 96.33% — and 2026, when it jumped 296.7%.
• Century Therapeutics' Long-Term Investments stood at $51.9 million in 2022, then soared by 71.82% to $89.1 million in 2023, then tumbled by 65.41% to $30.8 million in 2024, then tumbled by 91.27% to $2.7 million in 2025, then jumped by 2954.61% to $82.2 million in 2026.
• Business Quant data shows IPSC's Long-Term Investments at $82.2 million in Q1 2026, $2.7 million in Q2 2025, and $20.7 million in Q1 2025.